Novartis AG research snapshot
NVS AI stock analysis currently sees Novartis as a focused innovative-medicines company with durable positions in cardiovascular, renal and metabolic disease, immunology, neuroscience, and oncology. At the July 10, 2026 data cutoff, NVS closed at $154.62 and the mechanically verified market capitalization was $282.06 billion. The investment case rests on priority-brand growth and pipeline execution offsetting generic competition, patent exposure, deal risk, and drug-pricing pressure. This NVS AI stock analysis is an informational research tool, not investment advice.
Current price
$154.62
Market cap
$282.06 billion
AI score
75 / 100
Rating
High-quality innovative medicines business, moderate valuation support
Trend status
Long-term uptrend, consolidating below recent highs
Data cutoff (updated weekly)
July 10, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Novartis develops and commercializes prescription medicines, converting clinical evidence, regulatory approvals, manufacturing, and field access into recurring revenue from specialty therapies. | High |
| Moat | Patents, clinical data, regulatory know-how, physician relationships, manufacturing quality, and global distribution create meaningful barriers, although each franchise eventually faces competition. | Medium-high |
| Management | CEO Vas Narasimhan and the team should be judged on portfolio renewal, R&D productivity, bolt-on acquisition discipline, buybacks, and preparation for major product losses of exclusivity. | Medium |
| Financial trend | FY 2025 reported net sales were $54.532 billion and net income was $13.967 billion. Q1 2026 net sales were $13.113 billion and core EPS was $1.99. | High |
| Valuation | At $154.62 and $6.98 trailing EPS, NVS traded near 22.15x earnings and 16.82x free cash flow, leaving less room for execution misses than a deep-value pharmaceutical stock. | Medium-high |
| Technical trend | NVS remained above the cited 50-day and 200-day moving averages, while a 52.80 RSI described a neutral momentum reset after the early-July high. | Medium |
| Risk level | Risk is medium because of patent and generic exposure, clinical and regulatory uncertainty, drug-pricing pressure, foreign exchange, acquisitions, and the cost of replenishing the portfolio. | Medium-high |
| AI confidence | Reported data is well documented, but AI cannot establish the probability or commercial value of future trial outcomes and patent disputes. | High data confidence |
| Investment certainty | Medium certainty. NVS has a credible quality case, but the margin of safety depends on whether priority brands and launches replace mature-product pressure. | Medium |
NVS AI stock forecast
The NVS AI stock forecast uses scenario ranges instead of a precise price promise. The three-year model was calculated with financial_rigor.py using $154.62, $6.98 trailing EPS, and differentiated growth and terminal multiple assumptions. Analyst consensus also showed a $154.57 average target and Hold rating near the cutoff, which is a reference point rather than a forecast guarantee.
$220 to $235 over three years
More likely if priority brands and launches grow faster than mature products decline, pipeline readouts convert into durable revenue, margins hold, and investors maintain a premium multiple near 25x earnings.
$155 to $170 over three years
More likely if EPS grows around 5% annually, product losses of exclusivity are managed, guidance is met, and the market values NVS near 20x earnings.
$90 to $105 over three years
More likely if generic or biosimilar pressure accelerates, pipeline or regulatory setbacks emerge, pricing weakens, acquisitions disappoint, or the valuation compresses toward 15x earnings.
NVS AI technical analysis
NVS AI technical analysis was constructive but not decisive at the July 10, 2026 cutoff. StockAnalysis listed a $154.62 close on July 9, a 50-day moving average of $150.18, a 200-day moving average of $144.15, RSI of 52.80, and 20-day average volume of 2.19 million shares. Confirm all levels with a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $154.62 | NYSE closing price on July 9, 2026, used as the July 10 research cutoff snapshot. |
| Near support | $150 to $151 | The cited 50-day moving average was $150.18, making this the first trend-support area to monitor. |
| Major support | $144 to $145 | The cited 200-day moving average was $144.15. A sustained break below it would weaken the long-term trend. |
| Near resistance | $155.50 to $160.57 | This zone covers the July 6 close and July 2 intraday high in the cited price history. |
| 50-day moving average | $150.18 | StockAnalysis statistics listed this average at the cutoff. |
| 200-day moving average | $144.15 | Price remained above this average at the cutoff, supporting the longer-term trend view. |
| Momentum | RSI 52.80 | The cited RSI was near neutral, so it did not by itself confirm an overbought or oversold setup. |
| Volume | 2.19 million average shares | StockAnalysis listed 20-day average volume near 2.19 million shares. Breakouts need volume confirmation. |
| Volatility | Low beta, event-sensitive | The cited five-year beta was 0.50, but earnings, clinical data, regulation, and deal news can still produce gaps. |
| Invalidation | Close below $150, then $144 | A close below the 50-day average weakens the short-term setup. A break below the 200-day average calls for a new thesis review. |
NVS AI trading strategy
The NVS AI trading strategy is a rules-based research framework, not personalized advice. Use live prices, position sizing, loss limits, earnings dates, regulatory calendars, and current Novartis filings before placing a trade.
Watch for NVS to hold the $150 to $151 support area and reclaim the $155.50 to $160.57 resistance zone with volume that confirms demand.
A close below $150 or a failed breakout after a material company update should invalidate the short-term setup.
If NVS pulls back toward the 50-day or 200-day average without a new product, trial, pricing, or guidance problem, compare the price action with priority-brand sales and portfolio-replacement evidence.
Do not average down without a defined maximum loss because generic, regulatory, and clinical events can change the business case quickly.
Track priority-brand sales, Entresto and other mature-product erosion, core operating margin, R&D productivity, pipeline milestones, acquisitions, net debt, dividends, and buybacks.
Reduce confidence if apparent earnings resilience depends on one-off items, debt-funded capital returns, or launches that do not replace expected losses of exclusivity.
Investment research summary
Novartis sells differentiated prescription medicines. Customers pay for therapies with clinical evidence and regulatory approval that can improve outcomes in serious chronic and specialty diseases.
The moat rests on patents, clinical and real-world evidence, scientific expertise, regulatory capability, manufacturing quality, global commercial access, and physician trust. It is valuable but finite because drug exclusivity expires.
The thesis can fail if generic competition erodes key products sooner than replacement launches scale, clinical programs disappoint, payer and government price pressure rises, acquisitions destroy value, or debt and buybacks constrain flexibility.
Management must keep renewing the portfolio while balancing internal R&D, licensing, acquisitions, dividends, and buybacks. The important test is whether capital deployed today creates durable post-patent cash flows.
Aging populations and better diagnosis support demand for specialty medicines, but the same markets face tighter reimbursement, regulatory review, scientific competition, and political scrutiny of drug prices.
The verified valuation reflects a profitable, cash-generative pharmaceutical business rather than a distressed situation. The margin of safety improves only if portfolio renewal and earnings growth outpace mature-product erosion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NVS price | $154.62 closing price on July 9, 2026 | StockAnalysis historical price data, sourced from S&P Global Market Intelligence | July 10, 2026 |
| Market capitalization | $282.06 billion, verified as $154.62 x 1.824240085 billion implied shares | StockAnalysis market-cap snapshot and financial_rigor.py market-cap verification | July 10, 2026 |
| FY 2025 net sales | $54.532 billion reported by Novartis; StockAnalysis standardized financials list $56.674 billion, a 3.9% difference that may reflect data standardization or scope. | Novartis annual results and StockAnalysis cross-check | July 10, 2026 |
| FY 2025 net income | $13.967 billion reported by Novartis; StockAnalysis standardized financials list about $14.150 billion. | Novartis annual results and StockAnalysis cross-check | July 10, 2026 |
| Q1 2026 operating results | $13.113 billion net sales, $3.156 billion net income, $1.65 basic EPS, and $1.99 core EPS. | Novartis Q1 2026 interim financial report | July 10, 2026 |
| Cash and debt | $11.6 billion liquidity and $33.5 billion total financial debt at December 31, 2025. StockAnalysis listed $11.59 billion cash and short-term investments. | Novartis 2025 annual report and StockAnalysis balance-sheet cross-check | July 10, 2026 |
| Technical indicators | 50-day moving average $150.18, 200-day moving average $144.15, RSI 52.80, and 20-day average volume 2.19 million shares. | StockAnalysis statistics table | July 10, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available data and assumptions. They can be wrong, and readers should verify current information and consider their own objectives and risk tolerance.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
